Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata listed "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarter ended March 31, 2011
Business Stage: Clinical development stage company focused on patient-specific cell therapies for severe, chronic cardiovascular diseases, specifically Critical Limb Ischemia (CLI) and Dilated Cardiomyopathy (DCM). The company has not yet achieved profitability and relies on equity financing and grants.
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $9 | $0 |
| Net Loss | $(4,988) | $(2,679) |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.10) |
| Cash and Cash Equivalents (End of Period) | $24,621 | $17,844 |
| Net Cash Used in Operating Activities | $(6,419) | $(4,224) |
| Total Assets | $26,231 | $32,827 (Dec 31, 2010) |
| Warrant Liabilities | $24,700 | $25,954 (Dec 31, 2010) |
| Long-Term Debt | $43 | $41 (Dec 31, 2010) |
Note: Revenue for Q1 2011 consisted of $9,000 in product sales/rentals. The company reported no revenue from research agreements or grants for this specific quarter, though cumulative inception-to-date figures show significant grant revenue.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss widened to $4.99 million from $2.68 million year-over-year, driven primarily by increased Research and Development (R&D) expenses ($4.37M vs $2.85M) and Selling, General, and Administrative (SG&A) expenses ($1.90M vs $1.42M).
- R&D Spend Allocation: R&D costs for CLI increased to $2.35M (from $1.18M) and DCM to $2.00M (from $1.64M) due to Phase 3 preparation and clinical site setup.
- Non-Cash Income: The company recognized $1.25 million in non-cash income from the decrease in the fair value of warrant liabilities, partially offsetting the operating loss.
- Share Count: Weighted average shares outstanding increased significantly to 38.6 million from 26.7 million due to a December 2010 equity offering.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash on hand ($24.6M) is sufficient to fund operations until at least December 31, 2011. The company may need to delay discretionary hiring or non-critical R&D if necessary.
- Clinical Progress:
- CLI: Phase 2b RESTORE-CLI trial enrollment completed; interim data showed statistically significant improvement in time to treatment failure. The company expects to advance to a Phase 3 program in 2011 and has received FDA Fast Track Designation.
- DCM: Phase 2 surgical (IMPACT-DCM) and catheter-based trials are ongoing. Six-month interim data for the surgical trial indicated safety and positive efficacy trends.
- Material Weakness in Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to the accounting treatment of stock purchase warrants. This resulted in the restatement of prior financial statements. Management has hired new personnel and is implementing a remediation plan.
- Capital Needs: The company will require significant additional funding to complete Phase 3 trials and commercialize products. There is no assurance that such funding will be available on favorable terms.
Investor Verification Checklist
- Warrant Liability Accounting: Verify the impact of the Monte Carlo valuation methodology on future warrant liability fluctuations and potential non-cash income/expense volatility.
- Cash Burn Rate: Confirm the sufficiency of the $24.6M cash balance against the projected burn rate for the upcoming Phase 3 CLI trial.
- Regulatory Milestones: Monitor the status of the Special Protocol Assessment (SPA) agreements with the FDA for the Phase 3 CLI trial (expected Q2/Q3 2011).
- Internal Controls: Review future filings to confirm the remediation of the material weakness regarding warrant accounting.
- Dilution Risk: Assess the potential dilution from outstanding warrants (approx. 15 million shares) and options (approx. 7.6 million shares).